Merck & Co Inc at Jefferies London Healthcare Conference Transcript
All right. Good morning. Day 3 of our London Healthcare Conference. It has been a blast to see everyone here. I really do appreciate it.
Joining us -- my name is Akash Tewari. I'm a pharma and biotech analyst here at Jefferies. Joining me today is Merck, which is our topic in large-cap pharma. And joining us is Caroline Litchfield and Peter Dannenbaum, Head of IR. Caroline is CFO. Really, really appreciate the time. And Caroline told me she flew over just staying out with all of us today. So really appreciate that.
Maybe I can hand it to you for some brief introductory remarks, and then we can get into questions.
Yes. So first, can you hear me okay? First, thank you for having us, and thanks all for joining for this fireside chat. It's a really special time at Merck. As a company, we've got great momentum in our business. We're driving significant patient and customer impact across oncology, across vaccines,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
